Nature Medicine | Spoonful of Medicine

New drug pathways under investigation for ALS

A diagnosis of amyotrophic lateral sclerosis (ALS) is considered a life sentence. Most people with the neurodegenerative disease, which attacks the neurons responsible for motor control, only survive two or three years after their diagnosis — and 5,000 such diagnoses are made each year in the US alone. Despite the need, however, there is only a single drug on the market that targets ALS: Rilutek (riluzole), made by France’s Sanofi. But this agent only prolongs life by two or three months on average. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE